Interesting ImagesWidespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CTFan, Chunlei MD∗; Guo, Wei MD†; Su, Guoqiang MD, PhD∗; Chen, Bo MD, PhD∗; Chen, Haojun MD, PhD†Author Information From the Departments of ∗Colorectal Cancer Surgery †Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Received for publication April 23, 2020; revision accepted July 3, 2020. Informed consent and ethical approval: This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Xiamen University, and written informed consent for publication of this report was obtained from the patient. Conflicts of interest and sources of funding: The authors declare no conflicts of interest. This work was supported by the National Natural Science Foundation of China (grant no. 81801735 and grant no. 81701736). Correspondence to: Haojun Chen, MD, PhD, Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, 55 Zhenhai Rd, Xiamen 361003, China. E-mail: [email protected]. Clinical Nuclear Medicine: February 2021 - Volume 46 - Issue 2 - p e78-e79 doi: 10.1097/RLU.0000000000003245 Buy Metrics Abstract The present study compared 68Ga-FAPI and 18F-FDG PET/CT in a patient with GSRCC (gastric signet-ring cell carcinoma). In this case, 68Ga-FAPI PET/CT shows much higher tumor-to-background contrast of primary tumor and reveals more metastatic lesions than 18F-FDG PET/CT. This case demonstrates that 68Ga-FAPI PET/CT outperforms 18F-FDG in identifying both primary and metastatic lesions in GSRCC. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.